Octreotide (SMS 201-995) treatment of resistant acromegaly: Dosage considerations and range of hormonal effects

M. S. Magee, A. Manni, T. M. O'Dorisio, A. E. Boucher, L. Demers

Research output: Contribution to journalArticlepeer-review

Abstract

The case of a patient with acromegaly unresponsive to conventional therapies (surgery twice, bromocriptine, and radiotherapy) is presented. She was treated with gradually increasing doses of the somatostatin analog ocreotide (formerly SMS 201-995) with resultant near normalization of her somatomedin-C (10 U/ml pretreatment and 2.3 U/ml while receiving 1,200 ucg/day). Pretreatment evaluation revealed fasting and stimulated hyperinsulinemia, which was corrected as the growth hormone and somatomedin-C responded to treatment. There was no concomitant worsening of carbohydrate tolerance (as measured by three-hour oral glucose tolerance test (OGTT) and mixed meal tests) or glycemic status as ascertained by repeated measurement of fasting plasma glucose and hemoglobin A1C (HgbA1C). An improvement in insulin sensitivity is therefore implied. Enteropancreatic hormone profiling done in conjunction with three-hour OGTTs and mixed meal tests revealed a wide range of effects of octreotide upon different hormone secreting target cells. A brief review of current literature regarding octreotide treatment of acromegaly is discussed.

Original languageEnglish (US)
Pages (from-to)942-953
Number of pages12
JournalCurrent Therapeutic Research - Clinical and Experimental
Volume43
Issue number5
StatePublished - Jan 1 1988

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Octreotide (SMS 201-995) treatment of resistant acromegaly: Dosage considerations and range of hormonal effects'. Together they form a unique fingerprint.

Cite this